Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Dutasteride and finasteride don't raise erectile dysfunction risk.

CEC levels may be a useful marker for predicting prostate cancer progression.

In this study, researchers validated a computational workflow for repurposing non-antibacterial drugs as antibacterial agents and highlighted daprodustat, combined with an efflux pump inhibitor, as a promising strategy against bacterial pathogens.

This article updates on the medical management of benign prostatic hyperplasia in companion animals and reports no new clinical findings; the authors discuss existing treatments.

Self-management can help improve symptoms of benign prostatic hyperplasia.

This review discusses hormonal manipulation for conditions like prostatic disorders and skin issues and highlights promising treatments like casodex and finasteride, but it reports no new clinical results.

This review concludes that the global literature supports the efficacy and safety of lipidosterolic extract of Serenoa repens in treating lower urinary tract symptoms, comparable to alpha-blockers and 5α-reductase inhibitors.

This review discusses the integration of modern and Unani medicine in the management of Benign Prostatic Hyperplasia, highlighting the potential of Unani herbal formulations as promising alternatives with minimal side effects but reports no new clinical results.

This study found that frailty independently raises the risk of clinical BPH progression and serious adverse events in older men, suggesting that shared decision-making is essential when considering medical therapy for frail patients.

In this study, the ethanol extract of Zapoteca portoricensis stem significantly reduced markers of testosterone-induced benign prostate hyperplasia in male albino rats without harming liver and kidney function.

This review concluded that WS PRO 160 I 120 mg, a herbal preparation, may be an effective and safer alternative to standard drugs for treating lower urinary tract symptoms in men with benign prostatic hyperplasia.

This systematic review reported that among men taking finasteride for benign prostatic hyperplasia, total PSA levels decreased by 30% to 50%, and free PSA by up to 45%, with reductions in prostate volume and PSA density observed as well.

This study found that combining finasteride and anastrozole was more effective in preventing and treating benign prostatic hyperplasia in rats than using either drug alone.

This study found that Caesalpinia bonduc seed extracts significantly reduced prostate weight and improved prostate tissue morphology in Wistar rats with testosterone-induced benign prostatic hyperplasia.

In this review, the role of DHT in male-type obesity and metabolic diseases is discussed, with increased levels potentially exacerbating cardiovascular disease risk; the paper reports no new results.

This study found that LY320236 is a competitive inhibitor of type I and a non-competitive inhibitor of type II steroid 5alpha-reductase, indicating its potential as a dual inhibitor with differing modes of activity.

This study found that patients with non-muscle invasive bladder cancer who were treated with 5-alpha reductase inhibitors had lower recurrence rates and higher recurrence-free survival rates compared to untreated patients.

This review discusses current treatment options for androgenetic alopecia, noting that most lack robust evidence for efficacy and safety, highlighting the need for more comprehensive studies.

This review discusses the complex causes and treatment challenges of chronic inflammatory skin diseases, emphasizing the need for biomarkers to predict treatment responses; it reports no new clinical results.

This study reports the discovery of LX-38, a novel non-steroidal drug candidate that may offer safer treatment for conditions like Benign Prostatic Hyperplasia by avoiding hormonal side effects associated with current therapies.

This review discusses the potential uses of 5α-reductase inhibitors for conditions ranging from benign prostatic hyperplasia to skin disorders like acne and male pattern baldness, but it reports no new clinical results.

This review discusses the use of antiandrogens like flutamide and its derivatives in prostate cancer treatment and highlights the need for next-generation antiandrogens for improved efficacy; it reports no new clinical results.

This review discusses the use of 5α-reductase inhibitors, particularly finasteride, for treating conditions like benign prostatic hyperplasia, male baldness, and hirsutism, and reports no new clinical results.

This study reports that prostate volume, operation time, resected tissue weight, and smoking increase risks of blood loss and fluid absorption during PK-TURP, while finasteride treatment and surgeon experience may reduce these risks.

This review discusses the role of neurosteroids and androgens throughout different life stages, noting the potential disruptions caused by 5α-reductase inhibitors like finasteride, but no new clinical results are reported.

This study found that ureteroileal anastomosis with direct intraluminal visualization had a 4.2% stricture rate, which compares favorably to other techniques with rates between 3.5% and 11.1%.

This study observed improvements in hair loss, acne, and BPH symptoms after addressing vitamin D and progesterone deficiencies in male patients, suggesting the potential benefits of this therapeutic approach.

This study found that methylation of the 5-AR 2 promoter region may lead to low or absent 5-AR 2 protein expression in some human adult prostate tissues.

This review explores finasteride's effects on neuroactive steroid levels and their potential influence on disorders like depression and alcohol withdrawal but reports no new clinical findings.

New treatments for male hypogonadism are effective and should be personalized.